152 results on '"Fiala, Ondřej"'
Search Results
2. Pembrolizumab in patients with advanced upper tract urothelial carcinoma: a real-world study from ARON-2 project
3. Real-World Impact of Upfront Cytoreductive Nephrectomy in Metastatic Non-Clear Cell Renal Cell Carcinoma Treated with First-Line Immunotherapy Combinations or Tyrosine Kinase Inhibitors (A Sub-Analysis from the ARON-1 Retrospective Study)
4. Sex and survival outcomes in patients with renal cell carcinoma receiving first-line immune-based combinations
5. External validation of a red cell-based blood prognostic score in patients with metastatic renal cell carcinoma treated with first-line immunotherapy combinations
6. Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study
7. Use of concomitant proton pump inhibitors, statins or metformin in patients treated with pembrolizumab for metastatic urothelial carcinoma: data from the ARON-2 retrospective study
8. Papillary Renal Cell Carcinoma: Outcomes for Patients Receiving First-line Immune-based Combinations or Tyrosine Kinase Inhibitors from the ARON-1 Study
9. Alpha-methyl CoA racemase (AMACR) reactivity across the spectrum of clear cell renal cell neoplasms
10. Real-world effectiveness of pembrolizumab as first-line therapy for cisplatin-ineligible patients with advanced urothelial carcinoma: the ARON-2 study
11. Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study
12. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
13. Global Real-World Outcomes of Patients Receiving Immuno-Oncology Combinations for Advanced Renal Cell Carcinoma: The ARON-1 Study
14. Prognostic potential of whole exome sequencing in the clinical management of metachronous colorectal cancer liver metastases
15. Enfortumab Vedotin Following Platinum Chemotherapy and Avelumab Maintenance in Patients with Metastatic Urothelial Carcinoma: A Retrospective Data from the ARON-2EV Study.
16. Impact of Concomitant Cardiovascular Medication on Survival of Metastatic Renal Cell Carcinoma Patients Treated with Sunitinib or Pazopanib in the First Line
17. Exome Sequencing of Paired Colorectal Carcinomas and Synchronous Liver Metastases for Prognosis and Therapy Prediction
18. Giant Cell Temporal Arteritis Followed by Severe Encephalopathy Induced by Immunotherapy in a Patient with Metastatic Renal Cell Carcinoma Achieving Durable Partial Response: A Case Report.
19. Clinico-Pathological Features Influencing the Prognostic Role of Body Mass Index in Patients With Advanced Renal Cell Carcinoma Treated by Immuno-Oncology Combinations (ARON-1)
20. Concomitant antihypertensive medication and outcome of patients with metastatic castration‐resistant prostate cancer receiving enzalutamide or abiraterone acetate
21. Targeted panel sequencing of pharmacogenes and oncodrivers in colorectal cancer patients reveals genes with prognostic significance.
22. External Validation of a Red Cell-based Blood Prognostic Score in Patients With Metastatic Renal Cell Carcinoma Treated With First- Line Immunotherapy Combinations
23. Geographical differences in the management of metastatic de novo renal cell carcinoma in the era of immune-combinations
24. Outcomes of Patients With Long-Term Treatment Response to Vascular Endothelial Growth Factor-Targeted Therapy for Metastatic Renal Cell Cancer
25. Systemic Immune-Inflammation Index in Patients Treated With First-Line Immune Combinations for Metastatic Renal Cell Carcinoma: Insights From the ARON-1 Study.
26. Real-world Outcome of Patients with Advanced Renal Cell Carcinoma and Intermediate- or Poor-risk International Metastatic Renal Cell Carcinoma Database Consortium Criteria Treated by Immune-oncology Combinations: Differential Effectiveness by Risk Group?
27. Outcomes for Patients with Metastatic Renal Cell Carcinoma Achieving a Complete Response on Targeted Therapy: A Registry-based Analysis
28. Comparison of transcranial sonography-magnetic resonance fusion imaging in Wilson's and early-onset Parkinson's diseases
29. Spisová rozluka stavebních úřadů v kontextu zákona o archivnictví a spisové službě a návrh jejího řešení
30. EEG correlates of a mental arithmetic task in patients with first episode schizophrenia and schizoaffective disorder
31. Efficacy of sunitinib in patients with metastatic or unresectable renal cell carcinoma and renal insufficiency
32. Efficacy of everolimus in second- and third-line therapy for metastatic renal cell carcinoma: A registry-based analysis
33. Tyrosine kinase inhibitors in the first-line treatment for metastatic nonclear cell renal carcinoma: A retrospective analysis of a national database
34. EPMA-World Congress 2015: Bonn, Germany. 3-5 September 2015
35. Metformin Use and the Outcome of Metastatic Renal Cell Carcinoma Treated with Sunitinib or Pazopanib
36. The dominant role of G12C over other KRAS mutation types in the negative prediction of efficacy of epidermal growth factor receptor tyrosine kinase inhibitors in non–small cell lung cancer
37. CBIT - a new treatment method for tics and Tourette syndrome
38. 5. edice WHO klasifikace karcinomu prostaty z roku 2022: změny a novinky v „Blue Book".
39. Novinky WHO klasifikace z roku 2022: klasifikace renálních tumorů.
40. Circulating Tumor Cell Kinetics and Morphology from the Liquid Biopsy Predict Disease Progression in Patients with Metastatic Colorectal Cancer Following Resection
41. Novinky WHO klasifikace z roku 2022: klasifikace tumorů vývodných cest močových.
42. Remote Labs and Resource Sharing in Control Systems Education
43. Nivolumab-induced hepatitis in a patient treated for malignant melanoma
44. Side Effects and Efficacy of Immunotherapy
45. CBIT – nová léčebná metoda pro tiky a Touretteův syndrom.
46. Nové perspektivní jednotky: nádory ledvin popsané v době po WHO histopatologické klasifikaci z roku 2016.
47. Axitinib in the second-line treatment of metastatic renal cell carcinoma
48. Slaměný rodinný dům v obci Benešov u Semil
49. Octreotide in the treatment of malignant thymoma – Case report
50. Global methodology for developmental neurotoxicity testing inhumans and animals early and chronically exposed to chemicalcontaminants
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.